First year in Europe draws plenty of interest
Attended by more than 125 unique companies
SCOPE Europe 2018 at a glance
The successful launch of SCOPE Summit Europe, held 16-17 October, 2018 in Barcelona, Spain attracted more than 225 industry professionals. Across 2 days of in-depth discussions the Inaugural SCOPE Europe covered important issues in clinical
trial operations including Analytics-Driven Feasibility, Site Selection and Study Activation, Patient-Centric Enrollment Planning and Engagement, and Risk-Based Monitoring.
The global SCOPE Europe audience, with representation from 20 different countries and more than 125 unique organizations, came together for invaluable networking opportunities and sharing of best practices and lessons learned. More than 46% of
the audience were titled as a decision maker from leading Pharma (26%), CRO (34%), and Biotech companies (19%). With senior industry leaders and key decision makers present, SCOPE Europe provided important discussions and unique perspectives
on poignant issues that the field currently faces.
About the Event
Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning
and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, three conference tracks, interactive breakout discussion groups and networking. It is an opportunity for
leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials. Topics
to be discussed include protocol development, global site selection, feasibility, site management, patient engagement, enrollment planning, patient recruitment, patient retention, improving site-study activation and performance, functional/full-service
outsourcing and partnerships, new regulations and guideline, Risk-Based Monitoring (RBM), and improving overall quality and speed of clinical trials.